Coronary revascularization in patients with coronary artery disease and chronic kidney disease

Area of Science:

• Cardiology
• Nephrology
• Clinical Trials

Background:

• Patients with chronic kidney disease (CKD) have a significantly higher risk of cardiovascular disease (CVD), with CVD being the leading cause of mortality.
• Optimal management of coronary artery disease (CAD) in CKD patients remains poorly defined due to frequent exclusion from major clinical trials.
• There is a critical need for evidence-based guidelines to address CAD treatment in the CKD population.

Purpose of the Study:

• To review and synthesize the existing data on coronary revascularization outcomes in patients with chronic kidney disease (CKD).
• To highlight the challenges and limitations in current research regarding CAD management in CKD.
• To emphasize the importance of dedicated research for this vulnerable patient group.

Main Methods:

• Systematic review of published literature on coronary revascularization (e.g., percutaneous coronary intervention, coronary artery bypass grafting) in patients with varying stages of CKD.
• Analysis of studies comparing outcomes (e.g., mortality, major adverse cardiovascular events, renal function) between CKD and non-CKD populations undergoing revascularization.
• Discussion of data from observational studies and limited randomized trials, acknowledging methodological limitations.

Main Results:

• Evidence suggests that CKD patients undergoing coronary revascularization may experience different risk-benefit profiles compared to non-CKD patients.
• Outcomes such as mortality and graft patency in coronary artery bypass grafting (CABG) can be influenced by renal function.
• Data on the comparative effectiveness of different revascularization strategies (PCI vs. CABG) in CKD patients is scarce and often conflicting.

Conclusions:

• The optimal approach to coronary revascularization in patients with chronic kidney disease requires further investigation through well-designed clinical trials.
• Current evidence is insufficient to establish definitive treatment guidelines, necessitating careful individualized patient management.
• Future research should prioritize randomized controlled trials focusing on CAD treatment strategies specifically within the CKD population.